Showing results (101-110 of 108) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Nature Communications|July 20, 2019
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targetsFelicity Newell, Yan Kong, James S Wilmott, et al.The Lancet. Oncology|June 5, 2019
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trialElisa A Rozeman, Alexander M Menzies, Alexander C J van Akkooi, et al.The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.Annals of Surgical Oncology|January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.Nature|May 4, 2017
Whole-genome landscapes of major melanoma subtypesNicholas K Hayward, James S Wilmott, Nicola Waddell, et al.Nature Medicine|June 6, 2022
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trialIrene L M Reijers, Alexander M Menzies, Alexander C J van Akkooi, et al.Pathology|December 23, 2021
BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian settingRichard A Scolyer, Victoria Atkinson, David E Gyorki, et al.Nature Medicine|January 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trialLotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen, et al.Pageof 11